The Estoril 20th ERS Lung Science Conference (LSC) brought forward the importance of mucosal immunology through amazing presentations and posters and emka TECHNOLOGIES was happy to participate in this event.
The LSC 2022 showcased the on-going projects of researchers specialized in the pulmonary field. The variety of subjects tackled signified the importance of mucosal immunology and how we can have an impact on severe pulmonary diseases by targeting this side of the immune response.
We were particularly proud to see that our pulmonary products contributed to some of these great projects. Dr. Jonckheere’s work shed light on the potential role of innate lymphoid cells in non-allergic neutrophilic asthma model through a nice oral presentation and shared their analysis on these models’s airway hyperreactivity using the flexiVent.
Experimental models of chronic obstructive pulmonary disease (COPD) were also studied through an immune response lens. For instance, Dr. Van Eeckhoutte’s team showed that the inhibition of the RIPK1 kinase activity was proven to be protective in experimental models of COPD. Outcomes from the Pressure-Volume curves acquired using the flexiVent, highlighted this improvement of the lung function.
Another team focused on a potential therapeutic strategy to improve outcomes in early COPD mouse model by targeting CXCR4. Dr. Dupin’s team used the flexiVent to track changes in the lung obstruction by analyzing translation Flow-Volume curves of mice with a CXR4 deletion.
These promising results through focusing on the mucosal immune response when assessing different applications related to the lungs highlight exciting avenues for understanding the disease mechanisms and possible treatments.
When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.